Opendata, web and dolomites


Reversal of anti-cancer drug resistance

Total Cost €


EC-Contrib. €






Project "SCANRESIST" data sheet

The following table provides information about the project.


Organization address
postcode: 2100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2019-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCANDION ONCOLOGY DK (KOBENHAVN) coordinator 50˙000.00


 Project objective

Worldwide in 2018, cancer has been responsible for around 9.6 million deaths, and with a prediction of a further increase in incidence over the next years – which calls for urgent better treatment modalities to combat such deadly disease. Resistance to anticancer therapy is considered the main obstacle to successful clinical management of cancer patients. Scandion Oncology A/S (SCANDION) is a clinical-stage biotechnology company aimed to solve the anti-cancer drug resistance problem. We are developing a new drug, the SCO-101, which effectively targets some of the most common molecular resistance mechanisms in cancer. SCO-101 represent a paradigm shift in treatment of drug-resistant cancer, with multi mechanisms of actions in interfering with drug resistance. SCO-101 has previously passed four clinical phase I studies in healthy volunteers and proved to be a safe oral drug with very limited toxicity. The SCANRESIST project aims at performing clinical validation studies in taxane resistant breast cancer patients with open-labelled Phase II prospective clinical trial to establish SCO-101 Proof of Concept as a safe and efficient treatment modality. Our business model is based on out-licensing SCO-101 to pharma players active in anti-cancer drugs – who will be responsible for the remaining clinical development and market launch. The Phase II clinical validation has been pointed as a critical step achieve a deal with big pharma partners/licensees, which we know are interested in novel drugs with novel MoA, and with well-designed and well-performed phase II studies with positive results. Thus, the project will not only open a large market for SCANDION as it will also allow us to position the company as a unique provider of a new generation of anti-cancer resistance drugs – continuing our path on developing other drugs to combat drug resistance in cancer, innovative trial designs, predictive biomarkers and biomarker endpoints.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCANRESIST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCANRESIST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More